Progress of non-small-cell lung cancer with ROS1 rearrangement

Xin Yang; Zhe Tang; Jing Li; Jizong Jiang; Yue Liu

doi:10.3389/fmolb.2023.1238093

Progress of non-small-cell lung cancer with ROS1 rearrangement

Front Mol Biosci. 2023 Dec 22:10:1238093. doi: 10.3389/fmolb.2023.1238093. eCollection 2023.

Authors

Xin Yang¹, Zhe Tang², Jing Li¹, Jizong Jiang¹, Yue Liu³

Affiliations

¹ Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
² Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
³ Department of Thyroid and Breast Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Abstract

ROS1 rearrangement is found in 0.9%-2.6% of people with non-small-cell lung cancers (NSCLCs). Tyrosine kinase inhibitors (TKIs) target ROS1 and can block tumor growth and provide clinical benefits to patients. This review summarizes the current knowledge on ROS1 rearrangements in NSCLCs, including the mechanisms of ROS1 oncogenicity, epidemiology of ROS1-positive tumors, methods for detecting rearrangements, molecular characteristics, therapeutic agents, and mechanisms of drug resistance.

Keywords: ROS1 rearrangement; drug resistance; fusion gene; non-small-cell lung cancer; tyrosine kinase inhibitor.

Publication types

Review